| Name | Title | Contact Details |
|---|
Sonrava Health is the parent organization of a national family of health and wellness companies, united by a singular dedication to delivering high-quality, convenient and affordable care through innovative provider models, health coverage and product offerings. Building on a proven platform of success, the brand will continue to expand access to dental and vision care with a mission of advancing whole-person health for patients from all backgrounds. A geographically diverse, multi-specialty organization with a unique mix of providers and payors, Sonrava Health is comprised of several companies – including Western Dental & Orthodontics, Western Dental Kids, Brident Dental & Orthodontics, Brident Dental Kids, LooksBrite Eye Centers, EyeMax Vision Plan, MIB Insurance Plans, Vital Smiles, MID-Atlantic Dental Partners, DentalWorks, and Perfect Teeth – all united in our commitment to quality, value and innovation in care.
Barnes-Butler Inc is a Topeka, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cypress Palms welcomes you to our unique senior living community that offers everything you need and want in Assisted Living. From vibrant social programs and amenities that delight and entertain our residents to exceptional dining, abundant services and compassionate care; a great lifestyle tailored to your needs awaits you here.
Since our beginning in 1948, the Framingham Heart Study, under the direction of the National Heart, Lung and Blood Institute (NHLBI), formerly known as the National Heart Institute, has been committed to identifying the common factors or characteristics that contribute to cardiovascular disease (CVD). We have followed CVD development over a long period of time in three generations of participants.
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.